多吉美联合白细胞介素-2治疗转移性肾癌患者的近期疗效及安全性  

Term Efficacy and Safety of Nexavar Combined Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma

作　　者：张任[1] 赵黎[1] 

机构地区：[1]湖北医药学院附属东风医院肾内科,十堰442008

出　　处：《中国医药导刊》2014年第3期471-472,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨分析多吉美联合白细胞介素-2治疗转移性肾癌患者的近期疗效及安全性。方法:2009年以来转移性肾癌患者84例作为研究对象,按照分层随机分组法分为实验组和对照组。对照组给予多吉美治疗,实验组给予白细胞介素-2联合多吉美治疗。比较两组患者近期治疗有效率及不良反应发生率。结果:(1)对照组患者临床有效率为19.0%(8/42),完全缓解率为16.7%(7/42);实验组患者临床有效率为33.3%(14/42),完全缓解率为26.2%(11/42)。实验组有效率和缓解率均高于对照组患者,差异有统计学意义(P<0.05);(2)两药联合应用没有新的不良反应和副作用发生,但两药的常见不良反应依旧存在。结论:多吉美联合白细胞介素-2能够提高转移性肾癌患者的临床疗效,但不良反应的发生无减少,治疗过程应注意不良反应的治疗及预防,以提高转移性肾癌患者的生活质量。Objective：To analysis the term efficacy and safe of nexavar combined interleukin-2 therapy in patients with metastatic renal cell carcinomaty. Methods：Since 2009, 84 patients with metastatic renal cell carcinoma as research subjects were divided into experimental group and control group according to stratified random. Control group received Nexavar treatment, experimental group received interleukin-2 combined Nexavar therapy. Efficacy and incidence of adverse reactions were compared between the two groups. Results：（1） The clinically effective rate of control group was 19.0%（8/42）, complete remission rate was 16.7%（7/42）. While the clinical effective rate of experimental group was 33.3%（14/42）, complete remission rate 26.2%（11/42）. Experimental group have higher efficiency and remission rate in patients, the difference was statistically significant（P〈0.05）;（2） There was no new adverse reactions and side effects occur in the treatment, but two common adverse drug reactions still exist.Conclusion：Nexavar combined interleukin-2 can improve the clinical efficacy of metastatic renal cell carcinoma patients, but without reducing the occurrence of adverse reactions during treatment.We should pay attention to the treatment and prevention of adverse reactions in order to improve the quality of life in patients with metastatic renal cell carcinoma.

关 键 词：转移性肾癌 多吉美 白细胞介素-2 

分 类 号：R737.11[医药卫生—肿瘤]